An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)

Inclusion criteria

• Patients over 18 years old;
• Patients with left ventricular thrombus newly found by body surface ultrasound less than or equal to 3 months before selection, with no limitation on basic diseases;
• Patients who received standard anticoagulant therapy for less than 4 weeks before enrollment did not use antiplatelet drugs or only used single antiplatelet drugs;
• The patients voluntarily joined the study and signed the informed consent.

Exclusion criteria

• Patients with contraindications to rivaroxaban anticoagulation therapy;
• Patients with a history of acute pulmonary embolism or deep venous thrombosis within a week need intensive anticoagulant therapy;
• Patients with history of hemorrhagic stroke within one week;
• Patients with cardiac benign and malignant tumors;
• Aspirin and P2Y12 receptor antagonists should be kept;
• In patients with severe hepatic and renal insufficiency, alanine aminotransferase > 3 times the upper limit and total bilirubin > 2 times the upper limit, creatinine clearance rate < 15ml / min / 1.73m2;
• The patient's history of intracerebral hemorrhage and active hemorrhage was 8 months;
• Patients with hematological diseases, hemoglobin < 100g / L, platelet < 80 x 10^9 / L;
• Women with pregnancy status, planned pregnancy and lactation period;
• Patients with life expectancy less than 1 year;
• Patients enrolled in other clinical studies;
• Other situations considered unsuitable by the researcher. Note: anticoagulant therapy can be given to patients with left ventricular thrombosis combined with hemorrhagic stroke ≥ 4 weeks or recent ischemic stroke / transient ischemic attack according to the specific situation.